Professor Lisa Butler
Lead SAiGENCI Associate
South Australian Immunogenomics Cancer Institute
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Professor Lisa Butler is a full-time academic researcher in the South Australian Immunogenomics Cancer Institute (SAiGENCI) and the Freemasons Centre for Male Health and Wellbeing (FCMHW) at the University of Adelaide, and is Director of the Solid Tumour Program at the South Australian Health and Medical Research Institute (SAHMRI). She holds key executive positions in the FCMHW, the Australian Prostate Cancer BioResource, the Prostate Cancer Foundation of Australia and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.
- My Research
- Career
- Publications
- Grants and Funding
- Teaching
- Supervision
- Professional Activities
- Contact
Prof Butler has established an internationally-recognised research program focused on targeting androgen signalling in prostate cancer, discovering innovative biomarkers of response to treatment, and testing the efficacy of novel drugs for prostate cancer.
Prof Butler undertook postdoctoral studies at Memorial Sloan-Kettering Cancer Center in New York from 1998-2001. Her work there directly contributed to the clinical development of histone deacetylase inhibitors as anticancer agents and formed the basis of her interests in translational research. Since returning to Australia, a major focus of her research program has been the development of preclinical models that more closely represent the individual responses in men with prostate cancer. She developed the unique ex vivo tumor culture model, which has been applied to multiple tissues and resulted in the adoption of the technique by scientists from the University of Leuven, Belgium, Thomas Jefferson University, Philadelphia, UT Southwestern, Dallas and the Royal Marsden Hospital, London. Prof Butler’s research group has used this model to demonstrate the anti-proliferative efficacy of the novel heat shock protein 90 inhibitor AUY922 and the cyclin dependent kinase inhibitor ribociclib in prostate cancer tissues (Clin Cancer Res 18:3562), and funding was subsequently awarded by Cancer Australia in 2013 to translate these preclinical studies into an ongoing clinical trial of ribociclib for prostate cancer. From 2015-21 she led a Movember Revolutionary Team to investigate the role of lipids in prostate cancer and their potential for new biomarkers of disease aggressiveness, and in 2019 she and her collaborators were awarded funding from the US Department of Defense to further study the role of lipid metabolising enzymes in prostate cancer. Her other major research interests include development of novel combinatorial strategies to target the androgen receptor and lipid metabolism pathways in prostate cancer.
-
Appointments
Date Position Institution name 2022 - 2026 Head, Prostate Cancer Research Group University of Adelaide 2022 - ongoing Director, Solid Tumour Program South Australian Health and Medical Research Institute 2018 - 2022 Cancer Council Principal Research Fellow University of Adelaide 2014 - 2018 Australian Research Council Future Fellow University of Adelaide 2012 - 2013 University Senior Research Fellow University of Adelaide 2008 - 2012 Cancer Council SA Senior Research Fellow University of Adelaide 2006 - 2008 Florey Research Fellow University of Adelaide 2003 - 2005 Prostate Cancer Foundation of Australia Research Fellow University of Adelaide 2002 - 2002 NHMRC Senior Research Officer University of Adelaide 2001 - 2001 NHMRC Senior Research Officer Flinders University -
Awards and Achievements
Date Type Title Institution Name Country Amount 2021 Award Women in Leadership Award Cancer Council SA Beat Cancer Project Australia $60,000 2011 Nomination Nominated Delegate, NHMRC 75th Anniversary Symposium National Health and Medical Research Council Australia - 2004 Honour The Governor’s Leadership Foundation of South Australia The Governor’s Leadership Foundation of South Australia Australia - 2003 Award ILEX Oncology Scholar-in-Training Award American Association for Cancer Research United States - 2002 Award Bio-Rad New Investigator Award Australian Society for Medical Research Australia - 2001 Award Gerald B. Grindey Scholar In Training Award American Association for Cancer Research United States - 1997 Award AMRAD Young Investigator Award Australian Society for Medical Research Australia - 1996 Award The Ross Wishart Memorial Award Australian Society for Medical Research Australia - 1994 Award The R.F. Whelan Prize The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Australia - 1994 Award Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Prize The University of Adelaide Australia - -
Education
Date Institution name Country Title 1995 - 1998 University of Adelaide Australia PhD 1994 - 1994 University of Adelaide Australia BSC (Hons) 1991 - 1993 University of Adelaide Australia BSc -
Postgraduate Training
Date Title Institution Country 1998 - 2001 Postdoctoral Fellow Memorial Sloan Kettering Cancer Center, New York United States -
Research Interests
-
Journals
-
Book Chapters
-
Conference Papers
Year Citation 2022 Mak, B., Lin, H. -M., Mahon, K. L., Joshua, A. M., Stockler, M. R., Gurney, H., . . . Horvath, L. (2022). Modulation of the plasma lipidomic profile with simvastatin in metastatic castration-resistant prostate cancer (mCRPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40 (pp. 3 pages). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
DOI2017 Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Butler, L. (2017). Lipid elongation: an unexplored therapeutic target in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH.
DOI2017 Shafi, A. A., Schiewer, M. J., de Leeuw, R., McCue, P. A., Gomella, L. G., Lallas, C. D., . . . Knudsen, K. E. (2017). PDeX (Patient Derived eXplant) models to determine the basis for response to targeted agents in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH.
DOI2017 Tran, L. N. K., Kichenadasse, G., Ormsby, R. J., Morel, K. L., Butler, L. M., Centenera, M. M., & Sykes, P. J. (2017). COMBINATION OF METFORMIN AND SODIUM VALPROATE FOR PROSTATE CANCER: A RAPID APPROACH FROM BENCH TO CLINICAL TRIAL.. In JOURNAL OF UROLOGY Vol. 197 (pp. E1108-E1109). Boston, MA: ELSEVIER SCIENCE INC.
DOI2016 Tran, L. N. K., Kichenadasse, G., Morel, K. L., Ormsby, R. J., Butler, L. M., Centenera, M. M., & Sykes, P. J. (2016). Combination of metformin and valproic acid in personalized prostate cancer treatment: the role of p53 and androgen receptor signaling. In CANCER RESEARCH Vol. 76 (pp. 4 pages). New Orleans, LA: AMER ASSOC CANCER RESEARCH. 2016 Oesterreich, S., Katz, T., Logan, G., Levine, K., Nagle, A., Huo, Z., . . . Butler, L. (2016). Potential role of prolactin signaling in development and growth of the lobular subtype of breast cancer. In CANCER RESEARCH Vol. 76 (pp. 1 page). San Antonio, TX: AMER ASSOC CANCER RESEARCH.
DOI2016 Jankowitz, R., McAuliffe, P., Sikora, M., Butler, L., Ahrendt, G., Johnson, R., . . . Oesterreich, S. (2016). A neoadjuvant window trial of endocrine response in women with invasive lobular carcinoma. In CANCER RESEARCH Vol. 76 (pp. 2 pages). San Antonio, TX: AMER ASSOC CANCER RESEARCH.
DOI2015 Johnson, I. R. D., Parkinson-Lawrence, E. J., Butler, L. M., O'Leary, J. J., & Brooks, D. A. (2015). Altered Endosome Biogenesis in Prostate Cancer Has Prognostic Potential. In JOURNAL OF PATHOLOGY Vol. 237 (pp. S17). Univ Coll D, Dublin, IRELAND: WILEY-BLACKWELL. 2012 Ochnik, A. M., Moore, N. L., Birrell, S. N., Butler, L. M., Jindal, S., Selth, L., . . . Hickey, T. E. (2012). The combined actions of DHT and MPA lead to altered AR signaling in normal and malignant post-menopausal breast epithelial cells. In Cancer Research Vol. 72 (pp. 2). Chicago, IL: American Association for Cancer Research.
DOI2009 Lee, M., Labrinidis, A., Liapis, V., Hay, S., Zinonos, I., Butler, L., . . . Evdokiou, A. (2009). The histone deacetylase inhibitor, LBH589 blocks osteoclastogenesis, enhances osteoblast activity and reduces tumor burden in bone. In CANCER RESEARCH Vol. 69 (pp. 1 page). AMER ASSOC CANCER RESEARCH. 2009 Butler, L., Centenera, M., Marrocco, D., Carter, S., Bianco-Miotto, T., & Tilley, W. (2009). A novel combinatorial approach using androgen receptor-targeted agents for treatment of prostate cancer. In Cancer Research Vol. 69 (pp. 2 pages). American Association for Cancer Research. 2006 Murphy, N., Bianco-Miotto, T., Ricciardelli, C., Ruiz, A., Segara, D., McNeil, C., . . . Tilley, W. (2006). Expression of the androgen receptor and its association with disease outcome in breast cancer. In Breast Cancer Research and Treatment Vol. 100 (pp. S262-S263). San Antonio, Texas: Springer. 2005 Evdokiou, A., Minh, L. T., Labrinidis, A., Hay, S., Liapis, V., Bouralexis, S., . . . Findlay, D. M. (2005). Apo2L/TRAIL is a potent anticancer agent that prevents breast cancer-induced bone destruction in a mouse model. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 20 (pp. P35). Bethesda, MD: AMER SOC BONE & MINERAL RES. -
Conference Items
Year Citation 2023 Horvath, L., Lin, H. -M., Huynh, K., Meikle, T., Joshua, A. M., Azad, A., . . . Meikle, P. (2023). Circulating ether lipids in prostate cancer. Poster session presented at the meeting of Abstracts of the American Society of Clinical Oncology Annual Meeting I (ASCO 2023), as published in Journal of Clinical Oncology. Chicago, IL: Lippincott Williams & Wilkins.
DOI2023 Cilento, M. A., Mah, C. Y., Martelotto, L., Sweeney, C. J., & Butler, L. M. (2023). Multiomic analysis workflow for biomarker discovery in human prostate cancer. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2022 Strach, M. C., Yeung, N., Lin, H. -M., Ansari, N., Koh, C., Shin, J. -S., . . . Mahon, K. (2022). Patient-derived explant model of appendiceal cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. 2021 Lin, H. -M., Mak, B., Huynh, K., Kwan, E. M., Fettke, H., Tran, B., . . . Horvath, L. G. (2021). Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer. Poster session presented at the meeting of Abstracts of the European Society for Medical Oncology Congress (ESMO 2021), as published in Annals of Oncology. online: Elsevier.
DOI2020 Lin, H. -M., Huynh, K., Kohli, M., Tan, W., Azad, A., Yeung, N., . . . Horvath, L. (2020). Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism. Poster session presented at the meeting of Abstracts of the Mini Annual Scientific Meeting ANZUP 2020, as published in Asia-Pacific Journal of Clinical Oncology. Adelaide, SA: Wiley. 2020 Gieniec, K., Kobayashi, H., Lannagan, T., Wang, T., Asai, N., Mizutani, Y., . . . Worthley, D. (2020). Melanoma cell adhesion molecule defines a proliferative subset of leptin receptor-lineage cells that substantially contribute to the colorectal cancer stroma. Poster session presented at the meeting of JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. WILEY. 2020 Kobayashi, H., Gieniec, K., Wright, J., Wang, T., Asai, N., Mizutani, Y., . . . Woods, S. (2020). Stromal imbalance of bone morphogenetic protein signaling drives colorectal carcinogenesis. Poster session presented at the meeting of JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. WILEY. 2020 Shrestha, R. K., Townley, S., Hanson, A., Pickering, M., Nassar, Z. D., Mah, C. Y., . . . Selth, L. A. (2020). ACSM1 and ACSM3 regulate fatty acid oxidation in prostate cancer to promote growth and protect against oxidative stress.. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
WoS12020 Horvath, L. G., Lin, H. -M., Mak, B., Mahon, K., Yeung, N., Docanto, M., . . . Butler, L. (2020). Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
DOI2020 Butler, L. M., Mah, C. Y., Dehairs, J., Vincent, A., Mutuku, S., Spotbeen, X., . . . Swinnen, J. (2020). Phospholipid profiling of clinical prostate tissues reveals targetable alterations in membrane lipid composition accompanying tumorigenesis. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
DOI2020 Mah, C. Y., Nassar, Z. D., Burvenich, I. J., Irani, S., Centenera, M. M., Moldovan, M., . . . Butler, L. M. (2020). DECR1: The rate limiting enzyme of polyunsaturated fatty acid metabolism and a novel therapeutic target in prostate cancer. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
DOI2019 Shafi, A. A., Schiewer, M. J., de Leeuw, R., Dylgjeri, E., Mccue, P. A., Shah, N., . . . Knudsen, K. E. (2019). Patient derived models reveal impact of the tumor microenvironment on therapeutic response. Poster session presented at the meeting of CANCER RESEARCH. Atlanta, GA: AMER ASSOC CANCER RESEARCH.
DOI2019 Scheinberg, T., Kench, J., Stockler, M., Mahon, K. L., Sebastian, L., Stricker, P., . . . Horvath, L. G. (2019). Pharmacodynamics Effects of CDK4/6 Inhibitor LEE011 (Ribociclib) in High-Risk, Localised Prostate Cancer: A Study Protocol for a Randomised Controlled Phase II Trial (Leep Study). Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2019 Butler, L., Irani, S., Centenera, M., Ryan, N., Pegg, N., & Brooks, A. N. (2019). Preclinical investigation of a small molecule inhibitor of p300/CBP reveals efficacy in patient-derived prostate tumor explants.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS22018 Mutuku, S. M., Centenera, M. M., Trim, P. J., Snel, M. F., & Butler, L. M. (2018). Evaluation of small molecule drug uptake in <i>ex vivo</i> cultured clinical prostate tumours by mass spectrometry. Poster session presented at the meeting of BJU INTERNATIONAL. Brisbane, AUSTRALIA: WILEY. 2018 Zhang, A., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis after radical prostatectomy. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Adelaide: Wiley. 2018 Nassar, Z. D., Centenera, M. M., Machiels, J., Zinonos, I., Hanson, A., Bloch, K., . . . Swinnen, J. V. (2018). Lipid elongation in prostate cancer is androgen regulated and a potential therapeutic target. Poster session presented at the meeting of BJU International. Brisbane, Australia: Wiley. 2018 Butler, L. M. (2018). New Insights into Prostate Tumour Heterogeneity from Studying the "Lipidome". Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2018 Zhang, A., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis after radical prostatectomy. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Sydney: Wiley. 2018 Zhang, A. Y., Chiam, K., Haupt, Y., Fox, S. B., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy. Poster session presented at the meeting of Journal of Clinical Oncology. San Francisco, CA: American Society of Clinical Oncology.
DOI2017 Mutuku, S. M., Centenera, M., Trim, P., Gustafsson, O. J., Snel, M., & Butler, L. (2017). A Mass Spectrometry Approach to Characterise Lipid Composition in Prostate Tumuors. Poster session presented at the meeting of 11th Florey Postgraduate Research Conference. Adelaide. 2017 Aref, A. T., Vincent, A., O'Callaghan, M., Hoy, A., Butler, L., & Wittert, G. (2017). The inverse relationship between prostate specific antigen (PSA) and obesity in healthy men; support for a hormonal, rather than haemodilution mechanism. Poster session presented at the meeting of Abstracts of the 2017 ANZUP Annual Scientific Meeting, as published in Asia-Pacific Journal Of Clinical Oncology. Melbourne, VIC: Wiley.
DOI2017 Mutuku, S. M., Prabhala Bala., Centenera, M., Trim, P., Snel, M., & Butler, L. (2017). Quantification of Enzalutamide in Cultured Prostate Tissue Using LC-MS/MS. Poster session presented at the meeting of 26th Australian and New Zealand Society for Mass Spectrometry. Flinders University. 2017 Butler, L. (2017). IDENTIFICATION OF DRUG RESPONSE BIOMARKERS IN PATIENT-DERIVED PROSTATE EXPLANTS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2016 Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Swinnen, J. V. (2016). Androgenic regulation of lipid elongation in prostate cancer. Poster session presented at the meeting of BJU International. Melbourne: Wiley. 2015 Johnson, I. R. D., Parkinson-Lawrence, E. J., Brooks, D. A., Butler, L., & O'Leary, J. J. (2015). Altered Endosome Biogenesis in Prostate Cancer Identifies Potential Diagnostic Biomarkers. Poster session presented at the meeting of JOURNAL OF PATHOLOGY. Univ Coll D, Dublin, IRELAND: WILEY-BLACKWELL. 2015 Armstrong, H., Butler, L., Selth, L., Tarulli, G., & Centenera, M. (2015). The Hsp90 inhibitor, NVP-AUY922, produces anti-tumour activity through inhibition of fibronectin polymerization resulting in cytoskeletal reorganization. Poster session presented at the meeting of BJU INTERNATIONAL. Cairns, AUSTRALIA: WILEY-BLACKWELL. 2014 Roberts, M., Selth, L., Chow, C., Doi, S., Vincent, A., Butler, L., . . . Gardiner, R. (2014). Seminal fluid microRNAs: new, non-invasive biomarkers for prostate cancer. Poster session presented at the meeting of BJU International. Brisbane: Wiley. 2014 Zhang, A. Y., Butler, L. M., Stricker, P. D., Kench, J. G., Tilley, W. D., Sebastian, L., . . . Horvath, L. (2014). Pharmacodynamic effects of the heat shock protein 90 (HSP90) inhibitor, AUY922, in high-risk, localised prostate cancer. Poster session presented at the meeting of Asia-Pacific Journal Of Clinical Oncology. Melbourne, Vic.: Wiley.
DOI WoS12014 Philp, L. K., Day, T. K., Butler, M. S., Jindal, S., Butler, L. M., & Tilley, W. D. (2014). Full, but Not Partial, Sgta Ablation Confers Subfertility and Limits Offspring Viability and Growth in Mice. Poster session presented at the meeting of ENDOCRINE REVIEWS. ENDOCRINE SOC. 2014 Zhuang., Rodriguez Lopez., Chiam, K., Harryanto, H., Ryan, N., Jindal, S., . . . Bianco-Miotto. (2014). A high fat diet early in life and prostate cancer risk. Poster session presented at the meeting of The Australian Health and Medical Research Congress. Melbourne, Australia. 2013 Philp, L., Day, T., Jindal, S., Pickering, M., Butler, L., & Tilley, W. (2013). Protein expression alterations in a unique gleason prostate cancer progression cohort. Poster session presented at the meeting of BJU International. Melbourne: Wiley. 2013 Selth, L., Townley, S., Bert, A., Stricker, P., Sutherland, P., Horvath, L., . . . Tilley, W. (2013). CIRCULATING microRNAs PREDICT BIOCHEMICAL RECURRENCE IN PROSTATE CANCER PATIENTS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. 2012 Butler, L. M. (2012). DEVELOPMENTAL THERAPEUTICS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. 2010 Centenera, M. M., Treloar, J. L., Hanson, A., Sutherland, P., Tilley, W. D., & Butler, L. M. (2010). Evaluation of the synthetic heat shock protein 90 inhibitors NVP-AUY922 and NVP-HSP990 in human prostate cancer tissue. Poster session presented at the meeting of European Journal of Cancer Supplements. Berlin, Germany: Elsevier.
DOI2008 Hickey, T., Ocknik, A., Bianco-Miotto, T., Birrell, S., Butler, L., & Tilley, W. (2008). Functional androgen signaling in an explant model of normal human breast tissue. Poster session presented at the meeting of Biology of Reproduction. Kailua-Kona, Hawaii: Oxford University Press.
DOI2006 Buchanan, G., Ricciardelli, C., Prescott, J., Harris, J. M., Yu, Z. C. -L., Jia, L., . . . Tilley, W. D. (2006). αSGT: A critical determinant of androgen receptor function in prostate cancer. Poster session presented at the meeting of Cancer Research. Washington, DC: American Association for Cancer Research. -
Patents
Year Citation 2020 Brooks, D., Parkinson-Lawrence, E., Johnson, I., & Butler, L. (2020). 15/794,270, Methods for detecting prostate cancer by determining the ratio of early to late endosomal markers. United States. 2020 Brooks, D., O'Leary, J., Logan, J., Sorvina, A., Martino, C., Johnson, I., . . . Butler, L. (2020). PCT/AU2020/050925, Methods for Confirming Detection and Evaluating the Progression of a Prostate Cancer - II. Australia. 2014 Brooks, D., Parkinson-Lawrence, E., Johnson, I., Butler, L., & Weigert, R. (2014). PCT/AU2014/000612, Methods for detecting prostate cancer. Australia. 2003 Richon, V., Marks, P., Rifkind, R., & Butler, L. (2003). WO/2003/070188, Method of treating TRX mediated inflammatory diseases. United States Patent US2003235588. -
Preprint
Year Citation 2023 Cook, D., Jensen, K., Wise, K., Roach, M., Dezem, F. S., Ryan, N., . . . Martelotto, L. (2023). A Comparative Analysis of Imaging-Based Spatial Transcriptomics Platforms.
DOI2023 Wang, T., Harvey, K., Morlanes, J. E., Kiedik, B., Al-Eryani, G., Greenwald, A., . . . Martelotto, L. (2023). snPATHO-seq: unlocking the pathology archives.
DOI2023 Jiménez-Gracia, L., Marchese, D., Nieto, J., Caratù, G., Melón-Ardanaz, E., Gudiño, V., . . . Martelotto, L. (2023). FixNCut: Single-cell genomics through reversible tissue fixation and dissociation.
DOI
FELLOWSHIPS
- Cancer Council of SA Beat Cancer Principal Research Fellowship. BUTLER LM. From bedside to bench to bedside: improving prognosis and treatment of prostate cancer. 2018-2022. $600,000.
- Australian Research Council Future Fellowship. BUTLER LM. Molecular hallmarks of androgen receptor targeting in prostate cancer. 2014-2018. $846,240.
- Cancer Council of SA Senior Research Fellowship. BUTLER LM. Androgen Signalling in the normal human breast: role and implications for breast cancer risk. 2008-2012. $276,000.
- Royal Adelaide Hospital/IMVS Florey Research Fellowship. BUTLER LM. The role of androgen receptor signalling in the normal human breast. 2006-2008. $237,180.
- Prostate Cancer Foundation of Australia Postdoctoral Fellowship. BUTLER LM. Dominant negative androgen receptors: a novel strategy for treatment of advanced prostate cancer. 2003-2005. $300,000.
GRANT FUNDING
- Australian Research Council Discovery Project. BUTLER LM, Selth LA, Hoy AJ, Lynn DJ, Swinnen JV. Androgen receptor: a master regulator of lipid metabolism. 2023-2026. $614,000.
- Cancer Council NSW. BUTLER LM, Centenera MM. A patient-derived platform for drug development in prostate cancer. 2022-2025. $433,228.
- US Department of Defense. Labbe D, Corey E, Mucci L, Horvath L, Butler LM. Precision nutrition increases efficacy of DNA-damaging therapies in prostate cancer. 2022-2027. $USD 2,000,000.
- Cancer Australia. Selth LA, Wang S, BUTLER LM, Taylor RA, Holst J. Targeting CDK9 in lethal prostate cancer. 2022-2025. $459,000.
- Cancer Council of SA Women in Leadership Award. BUTLER LM. 2021. $59,976.
- The Hospital Research Foundation Prostate Cancer Project Grant. Centenera MM, BUTLER LM, Horvath LG. A patient-derived discovery platform for companion biomarker development in prostate cancer. 2021-2022. $149,662.
- The Hospital Research Foundation Prostate Cancer Project Grant. Nassar ZD, Xie J, BUTLER LM, Selth LA. Targeting Fatty Acid Oxidation for Treatment of High Risk Localised Prostate Cancer. 2021-2022. $149,956.
- Medical Research Future Fund Biomedical Translation Bridge (MTP Connect) / Envision Sciences Pty. Ltd./University of South Australia. Brooks DA, O’Leary JJ, Pursey P, Morretti K, Klebe S, Samaratunga H, Delahunt B, Karageorgos L, Esterman A, Dinan A, Brooks RD, Logan J, Sorvina A, Martino C, BUTLER L, Ung B Diagnosis and prognosis of prostate cancer using blood and tissue tests. 2020-21. $2,400,000.
- Tour de Cure Project Grant. Holst J, BUTLER LM. A new therapy targeting “gluttonous” prostate cancer cells. 2020-2021. $200,000.
- US Department of Defense Prostate Cancer Research Program Idea Development Award. Loda M, BUTLER LM, Swinnen JV. Lipid elongation via ELOVL5: a novel target for advanced prostate cancer. 2019-2022. $USD 736,817.
- UniSA Division of Health Sciences and UniSA Innovation Services. Brooks DA, Logan J, Martino C, Sorvina A, Johnson I, BUTLER L, Selemidis S, O’Leary J, Pursey P. UniSA Support Grant for Cancer Research Translation Programme. 2019-2022. $1,632,000.
- Cancer Australia Project Grant. BUTLER LM, Lynn DJ, Hayes VM, Horvath LG, Mills IG and Centenera MM. Novel co-extinction strategies for treatment of prostate cancer. 2017-2021. $596,409.
- Cancer Australia Project Grant. BUTLER LM, Horvath LJ, Tilley WD, Stocker M, Stricker PD and Kench JD. A randomised controlled Phase II trial of the pharmacodynamic effects of the Cdk4/6 inhibitor, LEE011, in high-risk, localised prostate cancer. 2016-2020. $590,408.
- Movember Foundation / Prostate Cancer Foundation of Australia Revolutionary Team Award. BUTLER LM, Swinnen JV, Tilley WD, Scott AM, Hoy AJ and Wittert GA. Exploiting alterations in lipid metabolism to improve diagnosis, treatment and molecular imaging of prostate cancer. Phase 1: 2015-2018. $3,250,000. Phase 2: 2019-2021. $2,000,000.
- Prostate Cancer Foundation of Australia Novel Concept Grant. BUTLER LM and Voelcker N. Next-generation prostate cancer therapies based on precision nanomedicines. 2017-2018. $99,919.
- Cancer Australia Project Grant. BUTLER LM, Daly R, Tilley WD, Horvath LG and Centenera MM. Molecular hallmarks of heat shock protein 90 inhibition in prostate cancer. 2015-2018. $553,483.
- NHMRC Development Grant. Brooks DA, BUTLER LM and O’Leary JJ. Development of effective biomarkers for the diagnosis and prognosis of Prostate Cancer. 2015-2017. $1,029,873.
- Cancer Australia Project Grant. Tilley WD, BUTLER LM, Plymate S and Selth LA. Mechanism and targeting of castration resistant prostate cancer. 2013-2015. $586,398.
- Ray and Shirl Norman Cancer Research Trust Research Grant. Tilley WD, BUTLER LM, Selth LA and Parnis F. Targeting androgen receptor variant signalling in lethal prostate cancer. 2013-2014. $327,184.
- Royal Adelaide Hospital Clinical Project Grant. Centenera MM and BUTLER LM. Evaluation of biomarkers of response to Hsp90 inhibition in human prostate cancer. 2013. $48,000.
- Royal Adelaide Hospital Clinical Project Grant. BUTLER LM, Brook N, Sutherland P and Saunders P. Development of an Australian prostate cancer reference cohort to support research identifying better biomarkers that predict disease progression. 2013. $18,000.
- Prostate Cancer Foundation of Australia New Directions Development Award. BUTLER LM, Centenera MM, Claessens F and Swinnen JV. Exploiting metabolic alterations to more accurately monitor prostate cancer therapy. 2012-2013. $299,817.
- Cancer Australia Project Grant. Tilley WD, BUTLER LM, Hoffman P, Goodall G and Scher HI. A novel approach to predict metastatic potential at prostate cancer diagnosis. 2011-2013. $591,732.
- Prostate Cancer Foundation of Australia Project Grant. Buchanan G, Kee T and BUTLER LM. Targeting chemokine signalling in prostate cancer. 2011-2012. $250,000.
- RAH/IMVS Research Committee Clinical Project Grant. Centenera MM, BUTLER LM and Tilley WD. Identification of biomarkers of response to Hsp90 inhibition in human prostate cancer. 2011. $20,000.
- Cancer Australia/Prostate Cancer Foundation of Australia Project Grant. BUTLER LM, Tilley WD and Scher HI. A combinatorial approach targeting androgen signalling for treatment of prostate cancer. 2010-2012. $589,673.
- NHMRC Project Grant. Tilley WD, BUTLER LM, Scher H and Bianco-Miotto T. The essential role of androgen receptor signalling in prostate tumorigenesis. 2010-2012. $813,913.
- RAH/IMVS Research Committee Clinical Project Grant. BUTLER LM. A novel explant model for the investigation of hormone signalling and novel treatments in human prostate tissue. 2010. $20,000.
- NHMRC Project Grant. Evdokiou A, Findlay DM and BUTLER LM. Histone Deacetylase Inhibitors (HDIs) with antineoplastic and antiosteolytic properties. 2008-2010. $513,750.
- US Army Medical Research and Material Command Congressionally Directed Medical Research Programs. Tilley WD, BUTLER LM and Marshall VR. Mechanism of Prostate Cancer Tumorigenesis. 2007-2010. $USD 482,622.
- NHMRC Project Grant. Tilley WD, BUTLER LM and Marshall VR. Androgen receptor signalling in development and progression of prostate cancer. 2007-2009. $723,750.
- National Breast Cancer Foundation of Australia. Androgen receptor status as a determinant of breast cancer risk. Tilley WD, BUTLER LM, Roder DM and Gelareh F. 2007-2008. $168,000.
- US Army Medical Research and Material Command Congressionally Directed Medical Research Programs. Kennaway DJ, Tilley WD and BUTLER LM. Disruption of the circadian rhythms of gene expression and the development of breast cancer. 2006-2008. $USD 381,818.
- National Breast Cancer Foundation of Australia. Evdokiou A, BUTLER LM and Findlay DM. TRAIL in breast cancer therapy. 2006-2008. $254,004.
- Cancer Council of South Australia. Tilley WD, BUTLER LM, Roder D and Farshid G. Androgen receptor status as a determinant of breast cancer risk. 2006. $76,000.
- The Susan G Komen Breast Cancer Foundation. BUTLER LM, Tilley WD and Birrell SN. Role of androgen signalling in the breast: disruption by synthetic progestins. 2005-2008. $USD 333,332.
- Cancer Council of South Australia. Evdokiou A, BUTLER LM and Findlay DM. Inhibition of breast cancer growth in, and metastasis to, bone using TRAIL therapy. 2005. $64,125.
- NHMRC Project Grant. Tilley WD, BUTLER LM and Marshall VR. Androgen receptor signalling and progression of prostate cancer. 2004-2006. $455,250,
- US Army Medical Research and Materiel Command, Breast Cancer Research Program. Kennaway DJ, BUTLER LM and Tilley WD. Clock genes: critical modulators of breast cancer risk? 2004-2005. $USD 99,485.
- US Army Medical Research and Materiel Command. Tilley WD, BUTLER LM and Birrell SN. The role of androgen receptor signalling in breast cancer. 2003-2006. $USD 350,121.
- NHMRC Project Grant. Tilley WD, BUTLER LM and Birrell SN. Inhibition of estrogen signalling by the androgen receptor: a potential mechanism of suppression of breast cancer cell growth by androgens. 2003-2005. $375,000.
PREVIOUS COMMERCIAL FUNDING
- Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, O’Leary JJ, Brooks RD, Logan J, Sorvina A, Martino C, BUTLER L, Johnson I, Hickey S, Selemidis S, Parkinson-Lawrence EJ, Orgeig S, Lazniewska J, Thomas C, Dale B, Ung B, Bader C, Morrow I, Chappell N, Moore C, Reynolds P, Esterman A, Karageorgos L. Development Program: Biomarkers and therapeutics for prostate and other cancers. 2020. $2,000,000.
- Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, O’Leary JJ, Brooks RD, Logan J, Sorvina A, Martino C, BUTLER L, Johnson I, Hickey S, Selemidis S, Parkinson-Lawrence EJ, Orgeig S, Lazniewska J, Thomas C, Dale B, Ung B, Bader C, Reynolds P, Esterman A, Olver I. Companion diagnostics and therapeutics for cancer. 2019. $2,350,000.
- AusHealth Project Grant. BUTLER LM, Ranieri E. Lipid screening for prostate cancer prognosis. 2018-2020. $200,000.
- Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, Plush S, Massi M, Brooks RD, O’Leary JJ, BUTLER L, Sorvina A, Bader C. Visualising the pathogenesis in cancer and developing novel therapeutics. 2017-2018. $1,019,225.
- Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, O’Leary JJ, BUTLER L, Johnson I, Selemidis S, Parkinson-Lawrence EJ, Sorvina A, Olver I, Esterman A. Prostate cancer diagnosis and prognosis. 2017-19. $2,930,165.
EQUIPMENT FUNDING
- Australian Cancer Research Foundation. Hughes TP, Zannettino ACW, White DL, Proud CG, Wesselingh SL, Lynn DJ, BUTLER LM, Gronthos S, Tilley WD and Bulone V. ACRF Centre for Integrated Cancer Systems Biology. 2018-2022. $2,500,000.
In addition to her extensive supervision of post-graduate students, Prof Butler has several roles in undergraduate teaching at The University of Adelaide.
LECTURING
- Biochemistry III – 3 lectures/year (2016-present)
- Masters of Biotechnology (Biomedical) – 1 lecture/year (2014-2017)
- Comparative Reproductive Biology of Mammals III - 1 lecture/year (2011-2017)
- Structural Cell Biology III – 6 lectures/year (2011-2016)
LABORATORY SUPERVISION
- Laboratory-based research projects as part of Level 3 Physiology and Medical Science, and Level 3 Biochemistry (2003-present)
- Summer vacation projects and scholarship program (2003-present)
STATE-WIDE RESEARCH TRAINING
- Teaching of annual workshop on Human Ethics for Laboratory Research- provided to all higher degree research students from the University of Adelaide, UniSA and Flinders University of SA (2009-2012)
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2024 Principal Supervisor Discovering lipid biomarkers of response to ribociclib in clinical prostate cancer tissues Doctor of Philosophy Doctorate Full Time Miss Suzanne Rajesh 2023 Co-Supervisor Novel Target Discovery for TP53 Mutated clonal Haematopoiesis Doctor of Philosophy Doctorate Full Time Mr Hossein Anani 2023 Principal Supervisor The impact of high fat diet on plasma ceramides and prostate tumour metastasis Doctor of Philosophy Doctorate Full Time Miss An Dieu Trang Nguyen 2023 Principal Supervisor Identifying novel metabolic drivers of lethal prostate cancer Doctor of Philosophy Doctorate Full Time Dr Michael Adam Cilento 2023 Co-Supervisor Examining the Influence of Fatty Acid Oxidation on Prostate Cancer Progression: An Epigenetic Exploration. Doctor of Philosophy Doctorate Full Time Mr Ez Aldeen Ismael Esawi 2023 Co-Supervisor Synthetic lethality-based identification of metabolic targets for prostate cancer treatment Doctor of Philosophy Doctorate Full Time Mr Mohammad Asaad Ibrahim Ismail 2023 Co-Supervisor How pluripotent transcription factors reshape the prostate cancer epigenetic landscape to reprogram the cell fate toward neuroendocrine-like with their cofactors Doctor of Philosophy Doctorate Full Time Mr Tianjun Zhang 2021 Co-Supervisor Overcoming resistance to cyclin-dependent kinase inhibition in prostate cancer Doctor of Philosophy Doctorate Full Time Mr Joshua Thomas Hodgson 2021 Principal Supervisor Spatial Lipidomics in Clinical Prostate Cancer Doctor of Philosophy Doctorate Full Time Mr Jacob Truong -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2020 - 2024 Co-Supervisor Investigating How Fatty Acid Elongation Promotes Prostate Carcinogenesis Doctor of Philosophy Doctorate Full Time Miss Deanna Catherine Miller 2019 - 2023 Principal Supervisor Lipid elongation and its role in prostate cancer Doctor of Philosophy Doctorate Full Time Miss Julia Steele Scott 2019 - 2023 Co-Supervisor Investigating USP2 as a mediator of therapy resistance in lethal prostate cancer Doctor of Philosophy Doctorate Full Time Ms Meiwen Danielle Fang 2018 - 2021 Principal Supervisor Investigating the Contribution of Specific Cancer-Associated Fibroblast Subsets to Colorectal Tumourigenesis Doctor of Philosophy Doctorate Full Time Miss Krystyna Anna Gieniec 2018 - 2024 Principal Supervisor Novel co-targets to improve androgen receptor inhibition in prostate cancer Doctor of Philosophy under a Jointly-awarded Degree Agreement with Doctorate Full Time Miss Josephine Ataa Hinneh 2018 - 2021 Principal Supervisor Targeting fatty acid metabolism in prostate cancer Doctor of Philosophy Doctorate Full Time Miss Chui Yan Mah 2017 - 2021 Co-Supervisor Elucidating the molecular mechanisms underlying androgen-regulated lipid metabolism in prostate cancer Doctor of Philosophy Doctorate Full Time Mr Raj Kumar Shrestha 2016 - 2019 Principal Supervisor Defining the Role of Lipids and Metabolic Factors as Risk Factors for Prostate Cancer Incidence and Aggressiveness Doctor of Philosophy Doctorate Full Time Dr Adel Aref 2016 - 2020 Principal Supervisor Understanding the Role of Androgen Receptor Signalling in Prostate Cancer:
A Lipidomics Approach by MALDI Mass Spectrometry ImagingDoctor of Philosophy Doctorate Full Time Mr Shadrack Mulinge Mutuku 2013 - 2016 Principal Supervisor Elucidating the Molecular Action of Synthetic Heat Shock Protein 90 Inhibitors in Prostate Cancer Doctor of Philosophy Doctorate Full Time Miss Heather Krista Armstrong 2013 - 2016 Co-Supervisor The Role of microRNA-194 and microRNA-375 in Prostate Cancer Metastasis Doctor of Philosophy Doctorate Full Time Dr Rajdeep Das 2008 - 2011 Co-Supervisor Investigating Lymphatic Vascular Remodelling During Postnatal Mouse Mammary Gland Morphogenesis Doctor of Philosophy Doctorate Full Time Ms Kelly Louise Betterman 2007 - 2015 Principal Supervisor Combinatorial Targeting of the Androgen Receptor for Prostate Cancer Therapy Doctor of Philosophy Doctorate Full Time Miss Sarah Carter 2006 - 2010 Co-Supervisor The Role of Epigenetic Modifications in Prostate Tumourigenesis Doctor of Philosophy Doctorate Full Time Ms Karen Huiqin Chiam 2004 - 2008 Co-Supervisor Characterisation of a Dominant Negative Androgen Receptor in Prostate Cancer Cells Doctor of Philosophy Doctorate Part Time Dr Margaret Centenera 2004 - 2008 Principal Supervisor Androgen Signalling in Normal and Malignant Breast Epithelial Cells Doctor of Philosophy Doctorate Part Time Ms Amelia Peters 2003 - 2007 Co-Supervisor Targeting the Androgen Receptor as a Therapeutic Strategy for Prostate Cancer Doctor of Philosophy Doctorate Full Time Miss Deborah Marrocco -
Other Supervision Activities
Date Role Research Topic Location Program Supervision Type Student Load Student Name 2020 - ongoing Co-Supervisor A comprehensive assessment of cancer cell metabolism University of Sydney - Doctorate - Nancy Santiappillai
-
Committee Memberships
Date Role Committee Institution Country 2021 - ongoing Chair Australian Prostate Cancer BioResource Executive Committee Australian Prostate Cancer BioResource Australia 2021 - ongoing Chair Research Committee Prostate Cancer Foundation of Australia Australia 2021 - ongoing Board Member National Board of Directors Prostate Cancer Foundation of Australia Australia 2020 - ongoing Member ANZUP Cancer Trials Group, Scientific Advisory Committee Australian and New Zealand Urogenital and Prostate (ANZUP) Australia 2018 - ongoing Chair BROCADE Tissue Access Committee Chair National Breast Cancer Foundation Australia 2017 - ongoing Member Research Advisory Committee Prostate Cancer Foundation of Australia Australia 2016 - ongoing Member Faculty of Health Sciences Research Committee The University of Adelaide Australia 2016 - ongoing Member Genomics Executive Committee South Australian Health and Medical Research Institute Australia 2015 - ongoing Member Appointments Committee South Australian Health and Medical Research Institute Australia 2014 - 2015 Chair School of Medicine Research Committee The University of Adelaide Australia 2013 - ongoing Member ANZUP Cancer Trials Group, Prostate and Translational Sub-Committee Australian and New Zealand Urogenital and Prostate (ANZUP) Australia 2012 - ongoing Convener Australian Prostate Cancer BioResource Executive Committee, Adelaide Node Coordinator Australian Prostate Cancer BioResource Australia 2012 - ongoing Member Australian Prostate Cancer Research - Scientific Member Australian Prostate Cancer Research Australia 2012 - 2015 Member NHMRC Postdoctoral Reference Group National Health and Medical Research Council Australia 2012 - ongoing Member NHMRC Research Translation Faculty National Health and Medical Research Council Australia 2011 - ongoing Member Freemasons Foundation Centre for Men's Health Executive Committee The University of Adelaide Australia 2011 - ongoing Member Movember Global Action Plan for Prostate Cancer - Functional Group Leader Movember Australia 2009 - ongoing Member Postgraduate Coordinator, Adelaide Medical School The University of Adelaide Australia 2009 - ongoing Member Australian Prostate Cancer BioResource Executive Committee Australian Prostate Cancer BioResource Australia 2007 - 2009 Member Institutional Biosafety Committee Institute of Medical and Veterinary Science Australia 2006 - 2013 Member School of Medicine Research Committee The University of Adelaide Australia 2004 - 2009 Member Institutional Biosafety Committee The University of Adelaide Australia 2003 - 2010 Member South Australian Breast Cancer Study Group Executive South Australian Breast Cancer Study Group Australia 2003 - 2005 Board Member Australian Society for Medical Research Australian Society for Medical Research Australia -
Memberships
Date Role Membership Country 2020 - ongoing Member Society for Basic Urological Research United States 2012 - ongoing Member Australian & New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group Australia 2011 - ongoing Member Centre for Personalised Cancer Medicine - University of Adelaide Australia 2006 - ongoing Member Hanson Institute Australia 2006 - ongoing Member Endocrine Society United States 2006 - ongoing Member Endocrine Society of Australia Australia 2004 - ongoing Member South Australian In Vivo Mouse Models Network Australia 2001 - ongoing Member Australian Prostate Cancer Collaboration Australia 1999 - ongoing Member American Association for Cancer Research United States 1995 - ongoing Member Australian Society for Medical Research Australia -
Community Engagement
Date Title Engagement Type Institution Country 2020 - ongoing Updates in prostate cancer research Public Community Engagement Mount Barker Prostate Cancer Support Group Australia 2020 - ongoing Overloading fats in prostate cancer cells is key to destroying them say researchers Public Community Engagement The Senior (online publication) Australia 2020 - ongoing Radio interview Public Community Engagement 5AA Adelaide Australia 2020 - ongoing Fat can kill cancer cells Public Community Engagement The Adelaide Advertiser (newspaper) Australia 2020 - ongoing Researcher Showcase Discussion Panel (Public Event) Public Community Engagement Cancer Council SA Australia 2019 - ongoing Working Together to Combat a Killer Public Community Engagement The Adelaide Advertiser (newspaper) Australia 2018 - ongoing Taking the Fight to Cancer Public Community Engagement The Adelaide Advertiser (newspaper) - 2018 - ongoing Defining Future Cancer Treatments, promotional video Public Community Engagement The University of Adelaide Australia 2017 - ongoing Lipids, obesity and prostate cancer Public Community Engagement Wealth and Wellbeing SAHMRI initiative launch for Bell Potter Securities Australia 2017 - ongoing Improving diagnosis, treatment and molecular imaging of prostate cancer Public Community Engagement SAHMRI Public Lecture Series - Cancer: Prevention, Diagnosis and Treatment (Public Event) Australia 2017 - ongoing New diagnosis and treatment tools for prostate cancer Public Community Engagement Lions Club Annual Meeting, Adelaide Australia 2017 - ongoing Networking advice for junior scientists Scientific Community Engagement Australian Society for Medical Research, Networking Event Australia 2016 - ongoing New markers for diagnosing prostate cancer Public Community Engagement Prostate Cancer Foundation of Australia Community Conversations (Public Event) Australia 2015 - ongoing Radio interview Public Community Engagement 5AA Adelaide - 2015 - ongoing Radio interview Public Community Engagement ABC Radio Adelaide Australia 2015 - ongoing Lipids, obesity and prostate cancer Public Community Engagement North Shore Prostate Cancer Support Group Australia 2015 - ongoing Prostate hope in pioneer test Public Community Engagement The Adelaide Advertiser (newspaper) Australia 2015 - ongoing Working overseas to build your CV and future career Scientific Community Engagement Australian Society for Medical Research, Networking Event Australia 2015 - ongoing World-first Cancer Research Public Community Engagement The Adelaide Review (newspaper) Australia 2015 - ongoing Radio interview Public Community Engagement ABC Adelaide radio Australia 2015 - ongoing Associate Professor Lisa Butler assembles world class team in bid to develop new biomarkers Public Community Engagement Prostate News (magazine) Australia 2014 - ongoing International research team formed to make impact on clinical care for prostate cancer patients Public Community Engagement The Lead SA (online newspaper) Australia 2014 - ongoing Prostate Team’s $3m Aim Public Community Engagement The Adelaide Advertiser (newspaper) Australia 2014 - ongoing Radio interview Public Community Engagement ABC Radio Adelaide Australia 2014 - ongoing Challenges in prostate cancer research (lay presentation) Public Community Engagement Royal Adelaide Hospital Australia 2014 - ongoing Public laboratory tours Public Community Engagement South Australian Health and Medical Research Institute Australia 2014 - ongoing Regular Consumer Advisory Group Meetings Public Community Engagement The University of Adelaide Australia 2012 - ongoing Radio interview Public Community Engagement 5AA Adelaide Australia 2012 - ongoing Challenges in prostate cancer research - Research Tuesday Public Lecture Series Public Community Engagement The University of Adelaide Australia 2012 - ongoing Towards improved management of breast and prostate cancer Public Community Engagement Cancer Care EXPO (Public Event) Australia 2011 - ongoing Probing the causes and treatment of prostate cancer Public Community Engagement Toshiba Medical presentation to radiology professionals Australia 2008 - ongoing Television news story Public Community Engagement Channel 9 Adelaide Australia -
Editorial Boards
Date Role Editorial Board Name Institution Country 2022 - ongoing Editor Molecular Cancer Research American Association for Cancer Research United States 2020 - ongoing Associate Editor Frontiers in Endocrinology - Systems Endocrinology Frontiers in Endocrinology United States 2019 - ongoing Board Member Journal of the National Cancer Institute Journal of the National Cancer Institute United States 2015 - ongoing Board Member Frontiers in Endocrinology Frontiers in Endocrinology United States 2015 - ongoing Board Member Frontiers in Oncology Frontiers in Oncology United States -
Review, Assessment, Editorial and Advice
Date Title Type Institution Country 2021 - ongoing Grant Review Grant Assessment European Science Foundation - 2020 - ongoing Grant Review Grant Assessment Swiss National Science Foundation Switzerland 2019 - ongoing Grant Review Grant Assessment Australia-India Strategic Research Fund Australia 2018 - ongoing Grant Review Grant Assessment ANZUP Below the Belt Fund Australia 2017 - ongoing Grant Review Grant Assessment Cancer Institute of NSW Australia 2017 - ongoing Grant Review Grant Assessment Prostate Cancer UK United Kingdom 2015 - ongoing Grant Review Panel Grant Assessment Health Research Council of New Zealand New Zealand 2015 - ongoing Research Advisory Committee Grant Assessment Prostate Cancer Foundation of Australia Australia 2015 - ongoing Grant Review Grant Assessment Cure Cancer Australia Australia 2015 - ongoing Grant Review Grant Assessment Cancer Research UK United Kingdom 2013 - ongoing Early Career Fellowships Review Panel Grant Assessment National Breast Cancer Foundation Australia 2012 - ongoing Grant Review Grant Assessment Cancer Council Australia 2012 - ongoing Grant Review Grant Assessment Prostate Cancer Foundation of Australia Australia 2012 - ongoing Grant Review Grant Assessment National Breast Cancer Foundation Australia 2011 - ongoing Grant Review Panel Grant Assessment Cancer Australia Australia 2010 - ongoing Oncology Grant Review Panels Grant Assessment National Health and Medical Research Council Australia 2005 - ongoing Grant Review Grant Assessment National Health and Medical Research Council Australia
Connect With Me
External Profiles